Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
OSA itself predicted the incidence of MACCE in non-obese patients.
Read Full NewsA retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in patients with metastatic urothelial carcinoma.
For women with invasive lobular carcinoma, pathogenic variants in breast cancer risk genes predict high odds of early recurrence.
Higher background parenchymal enhancement on breast MRI may signal greater risk among women who carry BRCA mutations.
Patients with relapsed or refractory diffuse large B-cell lymphoma, who were ineligible for autologous stem cell transplant, were randomly assigned to receive Pola-R-GemOx or R-GemOx.
1.
PSA Testing Is Not Enough for Another Candidate for Prostate Cancer Screening.
2.
As compared to proton therapy, proton therapy is very effective in treating esophageal cancer.
3.
Alkem introduces cetuximab under the trade name Cetuxa in India.
4.
Five new papers highlight cancer inequities, challenges and opportunities in South Asia
5.
Personalized Breast Cancer Treatment; Insights Into HPV in Men; Exercise and Cancer
1.
HPV Infection Review: Epidemiology, Risks, and Therapeutic Advances for Clinicians
2.
Angina Haemorrhagica Bullosa: What You Need to Know
3.
Exploring the Causes and Treatments of Cysts: A Comprehensive Guide
4.
Overcoming Immunotherapy Resistance: Novel Checkpoints, Biomarkers, and Emerging Therapeutic Strategies
5.
The Unseen Danger of Anal Cancer: How to Protect Yourself
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
5.
First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge